BCAB bioatla.com Expected Profit

Corporate company logo of BioAtla Corp (BCAB)

BioAtla, Inc. (BCAB) is developing innovative CAB antibodies that activate exclusively within tumors, thereby minimizing side effects. Patent protection and high selectivity create a robust barrier against competitors. The operating model relies on outsourcing production and clinical trials. The company's target profit dynamics demonstrate fundamental shifts, where the mark records this indicator.

BCAB - BioAtla Corp Expected Net Income over the range 07/04/2022 - 11/12/2026

Analytical breakdowns for BioAtla (BCAB)

- share price and consensus valuation forecast:
Stock Price BioAtla Inc|BCAB - Analyst Consensus Forecast
- market capitalization data:
Market Value BioAtla|BCAB - Total Company Value
- company book value details:
Accounting Value per Share BioAtla|BCAB - Accounting Value of Company|Market Value to Book Value Ratio bioatla.com|BCAB - Company Assets
- debt and solvency information:
Debt to Equity BioAtla, Inc.|BCAB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital BioAtla Inc|BCAB - Company Total Debt|Debt to Book Capitalization Ratio BioAtla|BCAB - Long-Term Debt|Company Short-Term Debt BioAtla|Quick Liquidity bioatla.com
- earnings and market ratios statistics:
BCAB - Company Net Income|Projected Future Earnings BioAtla, Inc.|BCAB - Market Cap to Net Income Ratio|Projected Price to Earnings BioAtla Inc|BCAB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio BioAtla|BCAB - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months BioAtla|BCAB - Earnings per share for the last four quarters|Quarterly EPS earnings growth bioatla.com|BCAB - Earnings per share increase in current year|Earnings growth forecast for next year BioAtla, Inc.
Comprehensive company analysis:BCAB, BioAtla, Inc.
Core merchandise of BioAtla

BioAtla, Inc. (BCAB) operates within the protected humanitarian oncology sector of the US, which minimizes external risks. This indicator assesses expected net income by comparing future cash flows with the current value of assets. Investors analyze this parameter to identify a fundamental bottom and avoid value traps. The forecast dynamics determine the business's actual margin of safety. Review the financial performance forecast to verify long-term growth potential.

Competitors of BioAtla, Inc.

INCY (Incyte Corporation) - Projected Future Earnings|Projected Future Earnings hutch-med.com|Expected Profit Nuvation Bio (NUVB)|Expected Profit DAWN (Day One Biopharmaceuticals, Inc.)|Monopar Pharma - Future Profit|Expected Net Income INBX|IMAB - Expected Profit|Expected Net Profit fennecpharma.com|herontx.com (HRTX) - Expected Profit|Net Profit Forecast NVCT|CHRS (Coherus Biosciences) - Projected Future Earnings|Future Profit Corbus Pharmaceuticals, Inc. (CRBP)|Expected Profit Cardiff Oncology, Inc. (CRDF)|BYSI - Expected Net Profit|Expected Profit Lixte Biotechnology Holdings, Inc. LIXT|Citius Pharmaceuticals Inc. - Expected Profit|CLRB - Expected Profit|Expected Net Profit BioLineRx Corporation|CANF: Projected Future Earnings|Projected Net Profit Aprea Therapeutics, Inc. APRE|Future Profit KZIA|Expected Net Profit Silexion SLXN|Future Profit NCNA (NuCana plc)|CMRX (Chimerix Inc) - Expected Net Income|Cyclacel Pharmaceuticals - Future Profit|Future Net Profit GTHX (G1 Therapeutics Inc.)|Kronos Bio - Projected Future Earnings|Expected Net Income KTRA (Kintara Therapeutics Inc)|ONCT: Projected Future Earnings|Expected Net Profit Portage Biotech Corp (PRTG)